EOC accounts for more than 90% of all ovarian carcinomas presented in the clinic, and 70% of these cases are high-grade serous ovarian cancers (HGSOC) overexpressing CA125 [25]. The gene discussed is MUC16; the disease is ovarian serous adenocarcinoma.